Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer

Yano, Tokujiro; Okamoto, Tatsuro; Fukuyama, Seiichi; Maehara, Yoshihiko

doi:10.5306/wjco.v5.i5.1048

Cited by 59 publications

(43 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Moreover, to allow early detection of LR and potentially cure LR, high-risk radiologic changes in the follow-up have been identified and discussed extensively. Unlike local recurrence after surgical resection of NSCLC, for which local treatments (surgery or radiotherapy) are indicated, 15,16 LR after SBRT for NSCLC presents a dilemma because local treatments for this patient cohort are challenging: most SBRT patients are inoperable and repeating SBRT or offering conventional radiotherapy in the same area is a safety concern and increases the risk of toxicity. Unlike local recurrence after surgical resection of NSCLC, for which local treatments (surgery or radiotherapy) are indicated, 15,16 LR after SBRT for NSCLC presents a dilemma because local treatments for this patient cohort are challenging: most SBRT patients are inoperable and repeating SBRT or offering conventional radiotherapy in the same area is a safety concern and increases the risk of toxicity.…”

mentioning

confidence: 99%

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer

Hamaji

Chen

Matsuo

et al. 2015

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer

Hamaji

Chen

Matsuo

et al. 2015

Journal of Thoracic Oncology

View full text Add to dashboard Cite

show abstract

“…NSCLC represented approximately 80% of all lung cancers . Surgery is the mainstay of therapy for the resectable stage III‐pN2 NSCLC, but local relapse and distant metastasis (DMs) would still occur after surgery frequently, disease recurrence after surgical resection reduces the patients’ life expectancy sharply . Researches show that Postoperative chemotherapy can reduce distant metastasis for patients with postoperative pathologically involved positive nodes .…”

Section: Introductionmentioning

confidence: 99%

Postoperative intensity‐modulated radiation therapy reduces local recurrence and improves overall survival in III‐N2 non‐small‐cell lung cancer: A single‐center, retrospective study

et al. 2020

View full text Add to dashboard Cite

Purpose:To determine the postoperative effects of radiotherapy (PORT) on the local recurrence-free survival (LRFS) and overall survival (OS) of stage III-N2 nonsmall-cell lung cancer (NSCLC). Materials and Methods: 183 patients with resected stage III-pN2 NSCLC from Hunan Cancer Hospital between 2013 and 2016 were divided into two groups for postoperative chemotherapy (POCT) (n = 105) or combination chemotherapy and radiotherapy (POCRT) (n = 78). The LRFS and OS were compared and the factors affecting local recurrence were illustrated in these two groups. The sites of failure based on the lobe of the primary tumor in two groups were described. Results: PORT leads to a strikingly lower risk for local recurrence and brought superior OS benefit. For different pN2 Subclassification, Patients with multiple-station pN2 ± pN1 disease had the worst LRFS (11 months) and single-station pN2 + multiple station pN1 disease had a relatively short LRFS (24 months) in group POCT. Short LRFS is correlated with multiple-station pN2, older age (Y > 55), patients with a high positive LN ratio > 1/3 and a poor tumor histological differentiation degree. In group POCT, the most frequent failure site occurs at the ipsilateral hilum (21.0%), the bronchial stump (20.0%), followed by LNs4R (19.0%), LNs4L (18.1%), LNs7 (15.2%), most of left-sided tumors more frequently involved the contralateral mediastinum, whereas the ipsilateral recurrences dominated for right-sided tumors, especially for LNs4R. In group POCRT, the highest failure site was the bronchial stump (11.5%), followed by LNs4L (8.97%), LNs1 (7.69%), the ipsilateral hilum (6.41%) and LNs4R (6.41%). Conclusion: PORT remarkably reduced local recurrence and improved OS in stage III-pN2 NSCLC, especially in the multiple-station pN2 group. CorrespondenceZhi-Gang Liu, The cancer center of the fifth affiliated hospital

show abstract

“…Metastasis is a major cause of morbidity and mortality in patients with NSCLC (4). Chemotherapy is the primary treatment for metastatic NSCLC (5). However, commonly used cytotoxic chemotherapeutic agents frequently display narrow therapeutic indices due to nonspecific cytotoxicity, undesirable side effects and intrinsic or acquired chemoresistance, which results in numerous cases of NSCLC being regarded as incurable (2).…”

Section: Introductionmentioning

confidence: 99%

Combined RNAi targeting human Stat3 and ADAM9 as gene therapy for non-small cell lung cancer

et al. 2015

View full text Add to dashboard Cite

Abstract. Previous studies have demonstrated that human signal transducer and activator of transcription 3 (Stat3) and disintegrin and metalloproteinase 9 (ADAM9) are promising targets for RNA interference (RNAi)-based gene therapy for human non-small cell lung cancer (NSCLC). Thus, in the present study, the recombinant lentiviral (Lv) small hairpin (sh)RNA expression plasmids Lv/sh-Stat3 and Lv/sh-ADAM9, which targeted Stat3 and ADAM9, respectively, were constructed and subsequently infected into the A549 human NSCLC cell line. Cell proliferation, migration, invasion and apoptosis were determined in vitro in A549 cells following treatment with Lv/sh-Stat3 or Lv/sh-ADAM9 alone or in combination. In addition, the combined effect of Lv/sh-Stat3 and Lv/sh-ADAM9 gene therapy was evaluated in vivo using A549 xenograft models in nude mice. The in vitro experiments demonstrated that A549 cells treated with a combination of Lv/sh-Stat3 and Lv/sh-ADAM9 exhibited a significant additive effect in their cell proliferation, migration, invasion and apoptosis abilities, compared with A549 cells treated with Lv/sh-Stat3 or Lv/sh-ADAM9 alone. The in vivo experiments conducted in A549 xenograft tumor mouse models revealed that the combined treatment with Lv/sh-Stat3 and Lv/sh-ADAM9 exerted an additive effect on tumor growth inhibition, compared with the treatment with Lv/sh-Stat3 or Lv/sh-ADAM9 alone. These results suggested that combined RNAi gene therapy targeting human Stat3 and ADAM9 may be a novel and promising strategy for the treatment of NSCLC. IntroductionLung cancer is the most common cause of cancer-associated mortality globally, and non-small cell lung cancer (NSCLC) is responsible for ~85% of cases of lung cancer (1,2). Despite the wide utilization of chemotherapy and radiotherapy for the treatment of advanced NSCLC, patient outcomes remain poor, with only <15% of patients surviving >5 years following diagnosis (3). Metastasis is a major cause of morbidity and mortality in patients with NSCLC (4). Chemotherapy is the primary treatment for metastatic NSCLC (5). However, commonly used cytotoxic chemotherapeutic agents frequently display narrow therapeutic indices due to nonspecific cytotoxicity, undesirable side effects and intrinsic or acquired chemoresistance, which results in numerous cases of NSCLC being regarded as incurable (2). Therefore, the development of novel and effective therapeutic strategies for the treatment of NSCLC is required.Signal transducer and activator of transcription 3 (Stat3), a member of the STAT family, is capable of regulating the expression of target genes implicated in cell cycle progression, apoptosis, promotion of cellular transformation and aberrant cell proliferation (6). Therefore, Stat3 represents an attractive target for therapeutic intervention. Previous studies using RNA interference (RNAi), dominant negative Stat3 and small molecule inhibitors have demonstrated that the inhibition of Stat3 signaling suppresses tumor cell proliferation and invasion, induces apoptosis in vitro an...

show abstract

Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer

Cited by 59 publications

References 43 publications

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer

Postoperative intensity‐modulated radiation therapy reduces local recurrence and improves overall survival in III‐N2 non‐small‐cell lung cancer: A single‐center, retrospective study

Combined RNAi targeting human Stat3 and ADAM9 as gene therapy for non-small cell lung cancer

Contact Info

Product

Resources

About